Do I have the only e-mail inbox clogged with more and more content about content marketing?
Do I have the only e-mail inbox clogged with more and more content about content marketing? You know, content marketing agencies or software vendors sending content about how you, too can learn to do content marketing? Add this to what I get from brands doing content marketing, and my inbox seems like an endless stream of information I may or may not need.
Such as…10 reasons to buy a VOIP phone system. Three sure-fire ways to develop precise personas. How you can increase your revenues 50% by following these 10 content marketing rules. And so on. Allow me to list the 15 reasons why I’m afraid to open my e-mail inbox each day. Stop the train, I want to get off. I’m sure there’s a useful e-book that will tell me how.
I’ve seen the stats that say it’s effective. NewsCred recently compiled 50 of them. For example, 60% of consumers feel more positive about a company after reading custom content on its site. Interesting content is a top 3 reason why people follow brands on social media. And, per dollar, content marketing generates three times as many leads as traditional marketing.
It’s not as if content marketing is a new approach. Inbound marketing techniques using information offers have been around from the beginning of the Paleolithic era. Learn 10 ways to kill a woolly mammoth. Download our e-book to make your own wheel. Mark your calendar for our free webinar on tips to keep you healthy until you’re well past the age of 26. Pharma marketing has always been content driven because brands are sold based on science and clinical data.
To a guy like me, it’s just become overwhelming. It certainly doesn’t seem like a marketing trend that’s sustainable for the long haul. Unless I start a new trend called Overload Marketing.
Al Topin is president at Topin & Associates, and a member of PharmExec’s Editorial Advisory Board. He can be reached at atopin@topin.com.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.